Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s consumer health joint venture with GlaxoSmithKline (GSK), which brought in cash intended to further improve and expand Novartis’ pipeline. Here we are. Yesterday, Novartis announced its intention to acquire the gene therapy firm AveXis (AVXS) at $8.7 billion, paying $218 for each share of this firm.

In a conference call on Monday, Dr. Narasimhan Novartis CEO confirmed that the acquisition will be partly funded by the GSK joint venture sale.
Why . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.